HUS requires treatment in the hospital. To ease signs and symptoms and to prevent further problems, treatment might include:

  • Fluid replacement. Lost fluid and electrolytes must be carefully replaced because the kidneys aren't removing fluids and waste as efficiently as normal.
  • Red blood cell transfusions. Red blood cells, transfused through an intravenous (IV) needle, can help reverse signs and symptoms of HUS including chills, fatigue, shortness of breath, rapid heart rate, yellow skin and dark urine.
  • Platelet transfusions. IV transfusions of platelets can help your blood clot more normally if you're bleeding or bruising easily.
  • Plasma exchange. Plasma is the part of blood that supports the circulation of blood cells and platelets. Sometimes a machine is used to clear the blood of its own plasma and replace it with fresh or frozen donor plasma.
  • Kidney dialysis. Sometimes dialysis is needed to filter waste and excess fluid from the blood. Dialysis is usually a temporary treatment until the kidneys begin functioning adequately again. But if you have significant kidney damage, you might need long-term dialysis.

Appropriate treatment leads to a full recovery for most people with HUS, especially young children.

If you have lasting kidney damage from HUS, your doctor might recommend a medication to lower your blood pressure, to prevent or delay further kidney damage. Your doctor might also recommend follow-up visits to evaluate your kidney function every year for five years.

Atypical HUS

This uncommon type of HUS is generally treated with plasma exchange. Your doctor might also recommend a medication — eculizumab (Soliris) — that can prevent the continued destruction of healthy cells. To prevent serious infection, you or your child might have a meningococcal vaccine before receiving this medication.

July 02, 2016
  1. Niaudet P. Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children. Accessed March 22, 2016.
  2. Niaudet P. Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) in children. Accessed March 22, 2016.
  3. Ferri FF. Hemolytic-uremic syndrome. In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016. Accessed March 23, 2016.
  4. Kliegman RM, et al. Hemolytic-uremic syndrome. In: Nelson Textbook of Pediatrics. 20th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. Accessed March 23, 2016.
  5. Tael MW, et al. Microvascular and macrovascular diseases of the kidney. In: Brenner & Rector's The Kidney. 9th ed. Philadelphia, Pa.: Saunders Elsevier; 2011. Accessed March 23, 2016.
  6. Greenbaum LA. Atypical hemolytic uremic syndrome. Advances in Pediatrics. 2014;61:335.
  7. Niaudet P. Complement-mediated hemolytic uremic syndrome. Accessed March 22, 2016.
  8. Keir LS. Shiga toxin associated hemolytic uremic syndrome. Hematology/Oncology Clinics of North America. 2015;29:525.
  9. Hemolytic uremic syndrome in children. National Kidney and Urologic Diseases Information Clearinghouse. Accessed March 23, 2016.
  10. Calderwood SB. Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC). Accessed March 22, 2016.